SearcharxivSearch

arXiv · 2504.12527

Analysis of the MICCAI Brain Tumor Segmentation -- Metastases (BraTS-METS) 2025 Lighthouse Challenge: Brain Metastasis Segmentation on Pre- and Post-treatment MRI

Nazanin Maleki·Raisa Amiruddin·Ahmed W. Moawad·Nikolay Yordanov·Athanasios Gkampenis·Pascal Fehringer·Fabian Umeh·Crystal Chukwurah·Fatima Memon·Bojan Petrovic·Justin Cramer·Mark Krycia·Elizabeth B. Shrickel·Ichiro Ikuta·Gerard Thompson·Lorenna Vidal·Vilma Kosovic·Adam E. Goldman-Yassen·Virginia Hill·Tiffany So·Sedra Mhana·Albara Alotaibi·Nathan Page·Prisha Bhatia·Melisa S. Guelen·Yasaman Sharifi·Marko Jakovljevic·Salma Abosabie·Sara Abosabie·Mohanad Ghonim·Mohamed Ghonim·Amirreza Manteghinejad·Anastasia Janas·Kiril Krantchev·Maruf Adewole·Jake Albrecht·Udunna Anazodo·Sanjay Aneja·Syed Muhammad Anwar·Timothy Bergquist·Veronica Chiang·Verena Chung·Gian Marco Conte·Farouk Dako·James Eddy·Ivan Ezhov·Nastaran Khalili·Keyvan Farahani·Juan Eugenio Iglesias·Zhifan Jiang·Elaine Johanson·Anahita Fathi Kazerooni·Florian Kofler·Dominic LaBella·Koen Van Leemput·Hongwei Bran Li·Marius George Linguraru·Xinyang Liu·Zeke Meier·Bjoern H Menze·Harrison Moy·Klara Osenberg·Marie Piraud·Zachary Reitman·Russell Takeshi Shinohara·Chunhao Wang·Benedikt Wiestler·Walter Wiggins·Umber Shafique·Klara Willms·Arman Avesta·Khaled Bousabarah·Satrajit Chakrabarty·Nicolo Gennaro·Wolfgang Holler·Manpreet Kaur·Pamela LaMontagne·MingDe Lin·Jan Lost·Daniel S. Marcus·Ryan Maresca·Sarah Merkaj·Gabriel Cassinelli Pedersen·Marc von Reppert·Aristeidis Sotiras·Oleg Teytelboym·Niklas Tillmans·Malte Westerhoff·Ayda Youssef·Devon Godfrey·Scott Floyd·Andreas Rauschecker·Javier Villanueva-Meyer·Irada Pflüger·Jaeyoung Cho·Martin Bendszus·Gianluca Brugnara·Gloria J. Guzman Perez-Carillo·Derek R. Johnson·Anthony Kam

Abstract

Despite continuous advancements in cancer treatment, brain metastatic disease remains a significant complication of primary cancer and is associated with an unfavorable prognosis. One approach for improving diagnosis, management, and outcomes is to implement algorithms based on artificial intelligence for the automated segmentation of both pre- and post-treatment MRI brain images. Such algorithms rely on volumetric criteria for lesion identification and treatment response assessment, which are still not available in clinical practice. Therefore, it is critical to establish tools for rapid volumetric segmentations methods that can be translated to clinical practice and that are trained on high quality annotated data. The BraTS-METS 2025 Lighthouse Challenge aims to address this critical need by establishing inter-rater and intra-rater variability in dataset annotation by generating high quality annotated datasets from four individual instances of segmentation by neuroradiologists while being recorded on video (two instances doing "from scratch" and two instances after AI pre-segmentation). This high-quality annotated dataset will be used for testing phase in 2025 Lighthouse challenge and will be publicly released at the completion of the challenge. The 2025 Lighthouse challenge will also release the 2023 and 2024 segmented datasets that were annotated using an established pipeline of pre-segmentation, student annotation, two neuroradiologists checking, and one neuroradiologist finalizing the process. It builds upon its previous edition by including post-treatment cases in the dataset. Using these high-quality annotated datasets, the 2025 Lighthouse challenge plans to test benchmark algorithms for automated segmentation of pre-and post-treatment brain metastases (BM), trained on diverse and multi-institutional datasets of MRI images obtained from patients with brain metastases.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Nazanin Maleki, Raisa Amiruddin, Ahmed W. Moawad, Nikolay Yordanov, Athanasios Gkampenis, Pascal Fehringer, Fabian Umeh, Crystal Chukwurah, Fatima Memon, Bojan Petrovic, Justin Cramer, Mark Krycia, Elizabeth B. Shrickel, Ichiro Ikuta, Gerard Thompson, Lorenna Vidal, Vilma Kosovic, Adam E. Goldman-Yassen, Virginia Hill, Tiffany So, Sedra Mhana, Albara Alotaibi, Nathan Page, Prisha Bhatia, Melisa S. Guelen, Yasaman Sharifi, Marko Jakovljevic, Salma Abosabie, Sara Abosabie, Mohanad Ghonim, Mohamed Ghonim, Amirreza Manteghinejad, Anastasia Janas, Kiril Krantchev, Maruf Adewole, Jake Albrecht, Udunna Anazodo, Sanjay Aneja, Syed Muhammad Anwar, Timothy Bergquist, Veronica Chiang, Verena Chung, Gian Marco Conte, Farouk Dako, James Eddy, Ivan Ezhov, Nastaran Khalili, Keyvan Farahani, Juan Eugenio Iglesias, Zhifan Jiang, Elaine Johanson, Anahita Fathi Kazerooni, Florian Kofler, Dominic LaBella, Koen Van Leemput, Hongwei Bran Li, Marius George Linguraru, Xinyang Liu, Zeke Meier, Bjoern H Menze, Harrison Moy, Klara Osenberg, Marie Piraud, Zachary Reitman, Russell Takeshi Shinohara, Chunhao Wang, Benedikt Wiestler, Walter Wiggins, Umber Shafique, Klara Willms, Arman Avesta, Khaled Bousabarah, Satrajit Chakrabarty, Nicolo Gennaro, Wolfgang Holler, Manpreet Kaur, Pamela LaMontagne, MingDe Lin, Jan Lost, Daniel S. Marcus, Ryan Maresca, Sarah Merkaj, Gabriel Cassinelli Pedersen, Marc von Reppert, Aristeidis Sotiras, Oleg Teytelboym, Niklas Tillmans, Malte Westerhoff, Ayda Youssef, Devon Godfrey, Scott Floyd, Andreas Rauschecker, Javier Villanueva-Meyer, Irada Pflüger, Jaeyoung Cho, Martin Bendszus, Gianluca Brugnara, Gloria J. Guzman Perez-Carillo, Derek R. Johnson, Anthony Kam. 2025-04-16. Analysis of the MICCAI Brain Tumor Segmentation -- Metastases (BraTS-METS) 2025 Lighthouse Challenge: Brain Metastasis Segmentation on Pre- and Post-treatment MRI. https://arxiv.org/abs/2504.12527

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

MarkerScout: A Disease-Agnostic Machine Learning Framework for Biomarker Prediction from Multi-Scale Mechanistic Models

We demonstrate the framework on three infectious diseases derived from a companion mechanistic immune-simulation platform: SARS-CoV-2, Influenza A Virus, and Plasmodium falciparum. Each disease was evaluated across hospitalization and intensive care unit cohorts, yielding six cohorts in total. Best-pipeline cross-validated macro F1 ranged from 0.82 for IAV-HOSP to 0.99 for COV-ICU, and the framework produced tiered, direction-aware biomarker lists for each disease and phase. Interleukin-18 (IL-18) reached the strongest tier in both SARS-CoV-2 phases with consistent direction. When benchmarked against three separate, independently collected clinical ICU datasets, MarkerScout's top-ranked features outperformed 94.4% of randomly selected feature sets of equivalent size for SARS-CoV-2, with a weaker but directionally consistent advantage for Influenza A Virus (66.7%) and Plasmodium falciparum (60.7%).

q-bio.OT

Enhancing Clinical Decision Support and Differential Diagnosis with Knowledge Graphs, and Retrieval Augmented Generation in Generative AI

Diagnostic error carries a burden, while unconstrained large language models (LLMs) remain vulnerable to hallucination and weak integration of quantitative laboratory dynamics. We developed a decision-support pipeline combining disease-specific biomarker correlation graphs, ordinary differential equations (ODEs), deep sequence classification, and retrieval-augmented generation (RAG). For 103 disease classes from a full blood count (FBC) repository, biomarker networks were used as coupling matrices to generate 30 trajectories per disease (3,090 total). A one-dimensional convolutional neural network (CNN) and long short-term memory (LSTM) network classified disease trajectories and six dynamical clusters. A constrained GPT-4o-mini RAG layer used a 19-pattern BMJ Best Practice/NICE corpus to generate differential diagnoses evaluated for diagnostic suitability, evidential grounding, and clinical plausibility. Across five random-seed runs, disease-level accuracy was $0.940 \pm 0.006$ for the CNN (95\% CI 0.933--0.948) and $0.852 \pm 0.019$ for the LSTM (95\% CI 0.828--0.875); the CNN advantage was 8.87 percentage points (95\% CI 6.47--11.27; $t(4)=10.26$, $p=5.1\times10^{-4}$; Hedges' $g=3.67$). Among 100 sampled RAG cases, 96 parsed successfully; evidence was cited in 97.9\%, the true diagnosis was mentioned in 71.9\%, and the composite score was 3.82/5 with a 47.9\% strict pass rate. The central finding was a decoupling between grounding and diagnostic correctness: classifier-correct versus classifier-wrong outputs differed in diagnostic suitability but not evidential grounding. Post-hoc analysis confirmed a 1.02-point diagnostic-score difference (Mann--Whitney $p=0.0024$; Hedges' $g=0.72$), whereas grounding differed by only $-0.02$ points ($p=0.839$; $g=-0.04$).

q-bio.OT

Expanding the Human Ancestry Ontology to include under-represented populations and ethnicities for broader utility in annotations

Successful discovery, integration and reuse of data relies on the availability of rich, well-structured and machine-readable metadata to describe every aspect of the data, from sample sources to collection processes to experimental protocols. The use of standardised terminologies to express concepts in a harmonised fashion lies at the core of high-quality data annotation, increasing the FAIRness of the data, facilitating data integration and promoting reproducibility. Here, we describe the Human Ancestry Ontology (HANCESTRO), originally developed to improve standardised reporting of genetic ancestry genomic resources such as the NHGRI-EBI GWAS Catalog and the Human Cell Atlas through high-level population descriptors, and more recently expanded to include diverse and previously under-represented populations in genomics and genetics research. HANCESTRO provides a framework for population descriptors that includes both ancestry based on the analysis of genetic information and self-reported ethnicity, which is based on social and cultural factors that don't necessarily align with genetic populations. By enabling the accurate and interoperable representation of population-related data, it promotes inclusive, representative and reproducible science.

q-bio.OT